VivoSeq
Oncology

Renal Carcinoma

13

Pipeline Programs↗

3

Active Trials↗

9

Companies Involved↗

Renal Carcinoma is an emerging landscape with 13 programs across 9 companies. The most active players are Bristol-Myers Squibb, EMD Serono, Essen Biotech. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2E

Essen Biotech

1 program

Phase 3Roche logo

Roche

1 program

Phase 3Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.

1 program

Phase 3Pacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

10 of 13 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody215%Protein / enzyme18%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Recruiting2 · 29%
Not yet recruiting1 · 14%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
Recruiting·CCentre Francois Baclesse·Phase 4·NCT07028125·83 enrolled
Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial
Recruiting·WWake Forest University Health Sciences·Phase 3·NCT07092566·170 enrolled
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Not yet recruiting·—·Phase 3·NCT06959433·20 enrolled
Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
Completed·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 3·NCT00502034·310 enrolled
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00455975·119 enrolled
Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study
Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT04134390·25 enrolled
Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
Terminated·National Cancer Institute (NCI)·Phase 2·NCT04150562·2 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)